high dose flu vaccine decreases severe cardiac and respiratory diseases

  

a recent study found that high dose flu vaccine in older adults was associated with of a decrease in a wide array of severe cardiovascular and respiratory outcomes, including hospitalization for heart failure: see flu vaccine high dose dec card dz Circ2026 in dropbox, or DOI: 10.1161/CIRCULATIONAHA.125.077801

Details:
-- this study was a prespecified secondary analysis of the unblinded FLUNITY-HD (Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes), which had individual-level pooled data sets integrating two methodologically harmonized (ie similar approaches), pragmatic, individually randomized trials conducted in Denmark and Spain, to assess the relative vaccine effectiveness of the high-dose inactivated influenza vaccine (HD-IIV) versus the standard-dose inactivated influenza vaccine (SD-IIV) against severe cardiovascular and respiratory outcomes (for the FLUNITY-HD see doi.org/10.1016/ S0140-6736(25)01742-8 in the Lancet)

    -- in particular, the study assessed the relative vaccine effectiveness of the two vaccines in those individuals ≥65 years of age who had or did not have pre-existing cardiovascular disease (CVD)
-- history of CVD was defined as a history of at least one of the following conditions within 10 years before randomization: ischemic heart disease, pulmonary embolism, valvular disease, cardiomyopathy, arrhythmia, cardiac arrest, heart failure (HF), cerebrovascular disease, peripheral vascular disease, or congenital heart disease

-- pooling of these two similar studies was integrated to increase the statistical power and generalizability of the results. these were 2 large-scale, largely methodologically consistent, individually randomized trials that were developed in a prespecified manner so that their results could be combined
    -- the DANFLU-2 study (332,438 individuals): a study in Denmark that enrolled adults ≥65 years of age, regardless of their living arrangements
    -- the GALFLU study (133,882 individuals): a study in Galicia, Spain that enrolled community-dwelling older adults 65 to 79 years of age, as well as those in nursing homes or ≥80 years of age in Galicia where the existing recommendation was for HD-IIV (which precluded randomization to SD-IIV). Individuals meeting the age-specific criteria were eligible for inclusion regardless of comorbidity. No additional eligibility criteria were involved.
        -- Both trials used pragmatic recruitment methods and invited participants primarily through electronic letters and text messages.
-- each trial was independently powered for the primary end point of hospitalization for influenza or pneumonia. The FLUNITY-HD pooled analysis was prespecified to secure sufficient statistical power in case of potentially lower than expected event rates in the individual trials, but also to provide increased statistical power for secondary analyses and to increase external validity by combining data from 2 separate countries with potential region-specific variations in clinical practices, influenza epidemiology, and health system structures.

Baseline characteristics of patients:
-- those with a history of cardiovascular disease (these numbers/percents were very similar between those receiving HD-IIV or SD-IIV):
    -- age 75, 35% female
    -- DANFLU had 45,688 (84.5% of the patients overall); GALFLU 8,373 (15.5%)
    -- cardiovascular events: ischemic heart disease 35%, MI 11%, atrial fibrillation 36%, heart failure 12%, vascular disease 16%, cerebrovasc disease 18%, peripheral arterial disease 4%
    -- diabetes 21%, cancer 16%, chronic kidney disease 21%, chronic lung disease 12%, COPD 7%, immunodeficiency 6%
    -- flu vaccine during preceding season 97%; co-administration with COVID-19 vaccine 67%, COVID vaccine during same season 96%
-- those without history of cardiovascular disease (these numbers/percents are very similar between those receiving HD-IIV or SD-IIV:
    -- age 73, 52% female
    -- DANFLU 120,875 (67% of the patients overall); GALFLU 58,720 (33%)
    -- diabetes 12%, cancer 7%, chronic kidney disease 7%, chronic lung disease 11%, COPD 3%, immunodeficiency 5%
    -- flu vaccine during preceding season 96%; co-administration with COVID-19 vaccine 72%, COVID vaccine during same season 96%
-- overall, many baseline characteristics were balanced across the HD-IIV and SD-IIV groups among participants with and without pre-existing CVD; however, there were some differences: participants with CVD were older (75 vs 73yo), more likely to be men (65% vs 48%), and more likely to have diabetes (21% vs 12%), chronic kidney disease (21% vs 7%), chronic lung disease (12% vs 5%), and cancer (16% vs 11%).

-- crude relative vaccine effectiveness (rVE) was calculated to reflect the effectiveness of the high-dose influenza vaccine versus standard-dose influenza vaccine in older adults

-- data were primarily obtained from routine health care databases, with follow-up from 14 days after vaccination to May 31 the following year.

primary end point of both trials as well as the combination study FLUNITY-HD: hospitalization for influenza or pneumonia
secondary end points of FLUNITY-HD: hospitalization for any cardiorespiratory disease, laboratory-confirmed influenza hospitalization, all-cause hospitalization, all-cause mortality, hospitalization for influenza, and hospitalization for pneumonia
    -- all primary and secondary end points were assessed according to the history of CVD, with the pre-specified cardiovascular end points: hospitalization for any CVD, respiratory disease, myocardial infarction, atrial fibrillation, or stroke
        --cardiovascular death and major adverse cardiovascular events were defined as a composite of myocardial infarction, stroke, or cardiovascular death
        -- and there was an alternative major adverse cardiovascular events end point that also included heart failure (HF) hospitalization

Results: 
-- the pooled data included 466,320 individually randomized older adults (332,438 from DANFLU-2 and 133,882 from GALFLU), of whom 107,700 (23.1%) had a history of CVD.

Primary and Secondary End Points Among Participants With and Without a History of Cardiovascular Disease

-- hospitalization for influenza or pneumonia (primary endpoint):
    -- individuals with known CVD: relative vaccine effectiveness (rVE) 7.6% (–3.2 to 17.3)
    -- individuals without known CVD: rVE 10.2% (0.4 to 19.1)
        -- Pinteraction =0.71; hence hospitalization for influenza or pneumonia was consistently reduced with HD-IIV among participants with and without known CVD
        -- number needed to vaccinate (NNV) to determine whether HD-IIV can provide additional benefit over SD-IIV: overall 1,839; CVD present 909; CVD absent 2,649

-- cardiorespiratory hospitalization (secondary endpoint):
    -- individuals with known CVD: rVE 6.0% (0.6 to 11.1)
    -- individuals without known CVD: rVE 7.2% (1.7 to 12.4)
        -- Pinteraction =0.75; hence cardiorespiratory hospitalization was consistently reduced with HD-IIV among participants with and without known CVD
        -- number needed to vaccinate (NNV) to determine whether HD-IIV can provide additional benefit over SD-IIV: overall 730; CVD present 329; CVD absent 1,150

-- hospitalization for laboratory-confirmed influenza (secondary endpoint):
    -- individuals with known CVD: rVE 34.7% (16.4 to 49.1)
    -- individuals without known CVD: rVE 29.8% (12.3 to 43.9)
        -- Pinteraction =0.66; hence laboratory-confirmed influenza hospitalization was consistently reduced with HD-IIV among participants with and without known CVD
        -- NNV to determine whether HD-IIV can provide additional benefit over SD-IIV: overall 2,003; CVD present 1,008; CVD absent 2,842

-- all-cause hospitalization (secondary endpoint):
    -- individuals with known CVD: rVE 2.6% (-0.5 to 5.6))
    -- individuals without known CVD: rVE 2.2% (-0.3  to 4.6)
        -- Pinteraction =0.84; hence all-cause hospitalization was consistently reduced with HD-IIV among participants with and without known CVD
        -- number needed to vaccinate (NNV) to determine whether HD-IIV can provide additional benefit over SD-IIV: overall 515; CVD present 303; CVD absent 650

-- hospitalizations for influenza (secondary endpoint):
    -- individuals with known CVD: rVE 45.7% (26.6 to 60.1)
    -- individuals without known CVD: rVE 34.4% (14.5 to 49.9)
        -- Pinteraction =0.35; hence all-cause hospitalization was consistently reduced with HD-IIV among participants with and without known CVD
        -- number needed to vaccinate (NNV) to determine whether HD-IIV can provide additional benefit over SD-IIV: overall 2,173; CVD present 1,076; CVD absent 3,127

-- here is the researchers' figure of the outcomes overall, for those without and those with prior cardiovascular disease:


as per the above figure, it is clear that the vast majority of the endpoints were on the HD-IIV side, and that the following reached statistical significance:
    -- the overall rate of hospitalization for influenza and pneumonia
    -- hospitalizations for any cardio-respiratory disease overall in both those with and without CVD
    -- all with laboratory-confirmed influenza hospitalizations
    -- the overall rate of all-cause hospitalizations
    -- all with hospitalization for influenza
-- though in the adjusted relative vaccine effectiveness (aRVE), adjusted for trial and season, these were statistically significant:
    -- hospitalization for any cardiorespiratory disease: the aRVE was 6.3 (2.5 to 9.9) with p=0.001 and NNV 730
    -- hospitalization for any cardiovascular disease: the aRVE was 6.6 (1.6 to 11.4) with p=0.010 and NNV 1217
    -- hospitalization for any respiratory disease: the aRVE was 6.5 (0.7 to 11.9) with p=0.010 and NNV 1577
    -- hospitalization for heart failure (an alternative major adverse cardiovascular event that was measured): the aRVE was 21.3 (7.6 to 33.0), p=0.003 
-- overall the results were mostly consistent in both of the individual trials in terms of these results. but for primary endpoint of hospitalization for influenza or pneumonia, DANFLU-2 reported no significant difference between the 2 vaccines

-- however,  patients in the DANFLU-2 group had more adverse events overall than those in the GALFLU group, felt likely to be from the older mean age of those in the former group (age 75 vs 73), though also likely from the different influenza seasons during which the studies were conducted that were more severe in Galicia than in Denmark

Commentary:
-- influenza infections are associated with significant morbidity and mortality, and studies have found that older adults fare worse: adverse cardiovascular outcomes from influenza are more common, including myocardial infarction, heart failure, stroke and atrial fibrillation
    -- influenza has both proinflammatory and prothrombotic effects and has been found to be associated with a 6-fold incidence of hospitalization for acute MI within one week of infection.
-- though there is some protection from cardiovascular events from the standard-dose inactivated influenza vaccine (SD-IIV), the high-dose inactivated influenza vaccine (HD-IIV) provides significantly greater protection in those ≥65yo
    -- there have been other studies finding that cardiovascular events are minimized with the HD-IIV vaccine. This study found benefit for respiratory events as well
-- the current study assessed whether individuals with pre-existing cardiovascular disease had more cardiovascular benefit  from HD-IIV vs SD-IIV, finding that there was no significant benefit from prioritizing the HD-IIV influenza vaccination to those with prior history of cardiovascular disease (CVD); ie, this translates clinically to the importance of vaccinating all individuals by the identified age range of ≥65yo, given the array of severe outcomes benefiting those receiving the HD-IIV: the overall rate of hospitalization for influenza and pneumonia, hospitalizations for any cardio-respiratory disease, all of those with laboratory-confirmed influenza hospitalizations, all with hospitalization for influenza, and the overall rate of all-cause hospitalizations
    -- though, as clear by the figure and numbers above, individuals with CVD do have a higher baseline risk of all-cause hospitalizations: for those with a history of CVD, 303 adults would need vaccination with HD-IIV instead of SD-IIV to prevent 1 all-cause hospitalization, with the number need to vaccinate adults without CVD would be 650 adults vaccinated with HD-IIV
    -- and, of note, for hospitalizations for heart failure (HF), there was a substantial reduction that was consistent in both of the individual trials, regardless of previous history of HF, with a pooled aRVE of 21.3% !!!

Limitations:
-- we do not have the specifics of the influenza types during the times of the above assessments in Galicia and Denmark. this would be useful information to allow better generalizability of the results, since there are outcome differences by the influenza type: did those individuals who had CVD do better with the SD-IIV than found above if their influenza type was only partially responsive to the vaccine?? [though, i think that is unlikely from other studies]  
-- there are potential misclassifications of patients in these studies. for example, patients with dyspnea could be categorized as heart failure when the issue may have been pneumonia or other respiratory disease
-- though the FLUNITY-HD had the immense statistical power at 466,320 individually randomized adults, and the analyses of specific cardiovascular outcomes and subgroups were prespecified in the statistical analysis plan, this initial study was not specifically powered for these analyses, and they were not included in the prespecified hierarchical testing sequence. this leads to a less rigorous statistical validity that could affect the results
-- this study did include patients from 2 different areas of the world, but there still may be very differences from other areas and thereby limit global generalization. for example, there are certainly many risk factors for cardio-respiratory diseases, and these do vary from one area to another
-- we have no information about the specifics of many of the outcomes: what type of heart failure was found, what kinds of cardiac diseases were found (arrhythmias, valvular heart disease) and what kind of vascular diseases.
-- there were significant differences in several of the pre-existing comorbidities (pretty much all of them) that were more prevalent in the group with CVD (not surprisingly), though neither the above study nor the original FLUNITY-HD study had any statistical analysis to equilibrate these differences (eg propensity matched scoring), and using such techniques would be more statistically valid and could alter the results

so,
-- yet another study finding that we should be using the HD-IIV vaccine in essentially all persons ≥65yo (as is the appropriate influenza vaccine in all guidelines in the US, though not uniformly so globally (https://www.ecdc.europa.eu/sites/default/files/documents/Seasonal-flu-vacc-recs-coverage-rates-EU-EEA.pdf)
-- this study does add a few important things to the argument for this vaccine, and this may be useful in convincing patients to get the HD-IIV:
    -- the benefit is broader than just cardiovascular protection, including decreased hospitalizations for influenza and pneumonia and all-cause hospitalizations
    -- and this applies to those with underlying cardiovascular disease, but just as much to those without CVD
    -- this study also provides information of the numbers needed to vaccinate with the HD-IIV vs SD-IIV vaccines, though the numbers needed to vaccinate with HD-IIV vs no vaccines is undoubtedly much less....
-- timing of the vaccine is complex. it is clear that the regular dose influenza vaccine has significant waning immunity pretty rapidly after the vaccination (https://gmodestmedblogs.blogspot.com/2018/09/maybe-we-should-delay-giving-flu-vaccine.html), but the high-dose vaccine has 4 times the antigen dose of the standard-dose one, and waning immunity seems to be less of an issue (though not rigorously tested, as with SD-IIV)
    -- and remember that it takes 2 weeks after vaccination to achieve clinical benefit

geoff

-----------------------------------

If you would like to be on the regular email list for upcoming blogs, please contact me at gmodest@bidmc.harvard.edu

to get access to all of the blogs:  go to http://gmodestmedblogs.blogspot.com/ to see the blogs in reverse chronological order


or you can just click on the magnifying glass on top right, then type in a name in the search box and get all the blogs with that name in them




Comments

Popular posts from this blog

air pollution and heart disease

UPDATE: ASCVD risk factor critique

visceral fat loss is sustained long-term